Ellex Medical Lasers (ASX: ELX) has now launched the company's proprietary Selective Laser Trabeculoplasty (SLT) technology in the U.S., which follows the expiration of a patent which prevented Ellex from selling its SLT technology in the country.
With the patent barrier removed, there is the potential for Ellex to deliver a positive impact on revenue during the first quarter of the 2014 financial year, as the company builds market share. Ellex hold a 40% market share on an international basis.
The company generated total revenue of $22 million for the first half of financial year 2013.
Since its approval by the FDA in 2001 and subsequent market introduction in the U.S. and worldwide, SLT has steadily become the therapy of choice for glaucoma.
The impact of SLT has been proven highly effective in over 250 published clinical papers with a strong safety profile, and it also overcomes the compliance issues and side effects of medications.
Ellex develops, manufactures and markets, lasers and diagnostic equipment for the treatment of eye disease to a growing global market, with the SLT an advanced laser therapy which stimulates a natural healing response in the eye to treat glaucoma.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.